Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice

Accumulating evidence indicates the role of endocrine disruptor bisphenol A (BPA) in many pathological conditions. Histone deacetylase (HDAC) inhibition has potential for the treatment of many diseases/abnormalities. Using a mouse BPA exposure model, this study investigated the hepatoprotective effects of the Food and Drug Administration–approved HDAC2 inhibitor valproic acid (VPA) against BPA-induced liver pathology. We randomly divided 30 adult male Swiss albino mice (8 weeks old; N = 6) into five groups: group 1, no treatment (sham control (SC)); group 2, only oral sterile corn oil (vehicle control (VC)); group 3, 4 mg/kg/day of oral BPA (single dose (BPA group)); group 4, 0.4% oral VPA (VPA group); and group 5, oral BPA + VPA (BPA + VPA group). At the age of 10 weeks, the mice were euthanized for biochemical and histological examinations. BPA promoted a significant decrease in the body weight (BW), an increase in the liver weight, and a significant increase in the levels of liver damage markers aspartate aminotransferase and alanine aminotransferase in the BPA group compared to SC, as well as pathological changes in liver tissue. We also found an increase in the rate of apoptosis among hepatocytes. In addition, BPA significantly increased the levels of oxidative stress indices, malondialdehyde, and protein carbonylation but decreased the levels of reduced glutathione (GSH) in the BPA group compared to SC. In contrast, treatment with the HDAC2 inhibitor VPA significantly attenuated liver pathology, oxidative stress, and apoptosis and also enhanced GSH levels in VPA group and BPA + VPA group. The HDAC2 inhibitor VPA protects mice against BPA-induced liver pathology, likely by inhibiting oxidative stress and enhancing the levels of antioxidant-reduced GSH.


Results
BPA and VPA effects on animal survival. The survival/mortality rates of the experimental groups were compared. No mortality and signs of acute toxicity were noted in all the studied groups. There was no significant difference between the SC and BPA groups.
HDAC2 inhibitor VPA positively affect the body and liver weights in mice after BPA exposure. To determine the effects of BPA exposure on the total body weight (TBW) and liver weight, the TBW of all experimental groups were monitored throughout the study period and the final body and liver weights recorded at the time of necropsy (Fig. 1). For the TBW, statistical analysis showed a significant difference in the mean TBW between BPA and control (SC and VC) groups (P < 0.0014; Fig. 1A), but VC showed no effect compared to SC. For BPA + VPA group, we observed a positive effect on the mean TBW compared to BPA group (P < 0.0089; Fig. 1A). The mean liver weight of BPA group increased compared to SC without statistical significance (P < 0.16; Fig. 1B). In contrast, VPA treatment after BPA exposure was effective against BPA-induced liver weight reduction (P < 0.0096; Fig. 1B) and restored the weight nearly to its normal level. www.nature.com/scientificreports/ HDAC2 inhibitor VPA attenuated liver damage markers in the sera of mice after BPA exposure. We investigated the effects of VPA on liver function in mice after BPA exposure by measuring the serum ALT and AST levels, which are markers of liver damage (Fig. 2). Significant ALT increase was noted in the BPA group compared to SC (P < 0.0018; Fig. 2A).
In contrast, we did not detect significant differences in AST levels between groups SC, VC and BPA group (P < 0.153; Fig. 2B). These results showed that BPA has toxic effects on liver function (hepatotoxicity). Compared to the BPA group, the BPA + VPA group showed a decrease in serum ALT and AST levels albeit without statistical significance ( Fig. 2A,B).
The HDAC2 inhibitor VPA alleviated liver pathology in mice after BPA exposure. Liver tissue from the SC group showed multifocal, lobular, lymphohistiocytic foci with minimal multifocal hyperemia and minimal multifocal erythrocyte extravasation (Fig. 3, panels i-iv). Compared to controls (sham and vehicle), liver tissue of the BPA group showed prominent hepatocellular degeneration (hydropic, panlobular, multifocal, mild), characterized by increased cytoplasmic granularity, cell swelling, and a pale cell cytoplasm with variable nuclei, usually not accompanied by infiltration, diagnosed as hepatocellular hydropic degeneration. We also found hepatocellular coagulative necrosis (panlobular, multifocal, mild), interpreted as cytoplasmic membrane disintegration, including cytoplasmic eosinophilic changes, karyopyknosis, karyolysis, and complete dissolution of nuclear chromatins of hepatocytes, accompanied by lympho-histiocytic infiltration with a few neutrophils (multifocal, mild). In addition, there was hepatocyte degeneration (centrilobular, multifocal, mild), described as swollen  www.nature.com/scientificreports/ hepatocytes with a pale, eosinophilic, finely vacuolated cytoplasm, interpreted as microvesicular hepatocellular steatosis. In addition, multifocal, lobular, lymphohistiocytic foci with minimal multifocal hyperemia and minimal multifocal erythrocytes extravasation were also seen, concentrated in portal tracts, which were considerably expended ( Fig. 3, panels iii-vi). In contrast, liver tissue from BPA + VPA group showed prominent hepatocyte regeneration and repopulation, demonstrated by various morphological changes, predominated by a regular histomorphological, lobular architecture, and hepatocyte proliferation, characterized by irregular, and thinking of hepatocyte cords and hepatocyte enlargement, containing two or more nuclei with prominent nucleoli, defined as binucleated, and multinucleated hepatocytes. Minimal multifocal hyperemia and minimal multifocal erythrocyte extravasation were also seen. Interestingly, histopathological investigation showed no appearance of pathologic hepatocellular necrosis, hepatitis, and/or distinct fibrosis (Fig. 3, panels vii, viii).
HDAC2 inhibitor VPA decreases hepatocellular apoptosis in mice after BPA exposure. Apoptosis analysis showed that BPA group showed a significant elevation in the hepatocyte death rate compared to SC (P < 0.0012; Fig. 4B); VC did not show any effect under control conditions (data not shown). In contrast, the BPA + VPA group showed a significantly decreased hepatocyte death rate (P < 0.0022; Fig. 4B). Liver tissue sections from all experimental groups were stained with H&E (Fig. 4A).
The percentage of apoptosis of hepatocytes was determined using strict morphological criteria 54 . Cytomorphological evidence of the BPA group showed significant hepatocyte apoptosis, represented by prominent chromatin condensation, DNA fragmentation, cytoplasmic vacuolation, and apoptotic body formation, accompanied by cell-related degenerative changes (Fig. 3). SC did not show hepatocyte apoptosis features. Statistically, the BPA group showed a significant augmentation in hepatocyte apoptosis rate compared to SC (P < 0.0001; Fig. 4C). the BPA + VPA group showed significantly decreased hepatocyte apoptosis (P < 0.0021; Fig. 4C). These results indicated that VPA treatment induces a protective (antidote) effect against BPA-induced cell injury, including hepatocyte apoptosis.
HDAC2 inhibitor VPA modulates oxidative and antioxidative status in mice after BPA exposure. The BPA group showed significantly increased lipid peroxidation, as revealed by increased MDA levels in the liver tissue, compared to SC (P < 0.0001; Fig. 5A). In addition, there was a significant elevation in protein peroxidation, as determined by protein carbonyl (PC) levels (P < 0.00001; Fig. 5B). In contrast, PC and MDA

Condensation
Cell www.nature.com/scientificreports/ levels in the liver tissue of the BPA + VPA group significantly decreased compared to the BPA group and were restored nearly to their normal levels (P < 0.0017 and P < 0.0006, respectively; Fig. 5A,B). Impact assessment of VPA's effect on the antioxidative status in mice after the BPA exposure compared the liver GSH levels in SC. BPA group had lower liver GSH levels matched to SC (P < 0.05; Fig. 5C), indicating that VPA treatment enhances GSH levels compared to BPA-untreated mice without statistical significance (P > 0.05; Fig. 5C).

Discussion
This study showed that BPA significantly induces liver pathology, as demonstrated by biochemical tests and histopathological findings. BPA in particular decreases the BW and increases the liver weight compared to controls, parallel to increased levels of liver enzyme indices (AST and ALT levels), hepatocellular apoptosis, hepatocyte injury scores, and oxidative stress indices (MDA and PC levels). There is also a decrease in GSH levels. Many of these noxious effects are attenuated by VPA treatment, which suggests an important role for the HDAC2 inhibitor VPA in BPA-induced injury and also indicates that decreasing oxidative stress and increasing GSH levels could contribute to the protection provided by VPA.
HDAC inhibitors have emerged as potent therapeutic agents in a range of diseases/abnormalities, since they have the ability to accelerate histone acetylation, alter the transcription of associated genes, and protect tissues 36 . Brain cultures of mice exposed to 50 mg/kg of BPA in their diet showed that in the promoter region of Kcc2 (the ion channel responsible for excreting chloride ions to the extracellular fluid), BPA-induced DNA hypermethylation and decreased histone acetylation. In addition, the MeCP2 expression and the ability of BPA to enhance the binding of MeCP2 to the Kcc2 promoter increased, decreasing the expression of Kcc2 55 , indicating a relationship between a decrease in acetylated histone and HAT inhibition and/or HDAC activation after BPA insult, which can be prevented by HDACi treatment.
The HDAC2 inhibitor VPA is widely used for neurological abnormalities such as epilepsy, bipolar disease, and some painful neuropathies 48 . It inhibits HDAC classes I and II, but not class III 48 . Because of their effect on acetylation sites, HDACi could be used as therapeutic agents. Currently, 18 different HDACs have been identified in mammals 36,46 . However, the roles of the different HDAC isoforms and HDACi in models of toxicant-induced liver injury are unclear. Therefore, this study focused on the efficacy of the HDAC2 inhibitor VPA against BPAinduced liver pathology.
Increased serum transaminases are a sign of liver damage and were reported in rats treated with 5 mg/kg/ day of BPA, but not with < 5 mg/kg/day of BPA 56 . In male rats treated with ≥ 200 mg/kg/day of BPA, Yamasaki et al. found increased AST activity and increased ALP and glutamyl transpeptidase activities in those treated with 600 mg/kg/day of BPA 57,58 . In this study, 4 mg/kg of BPA significantly raised serum levels of liver enzymes (high levels of ALP and ALT) compared to controls, which are attributed to liver injury. Treatment with VPA after BPA exposure modulated serum AST and ALT levels.
Increasing evidence shows that BPA may be hepatotoxic. BPA exposure is linked to an increased risk of being overweight 59 . Prenatal and early postnatal BPA exposure is correlated with increased BW 9,60-62 . Significant decline in BW was found in the group treated with 0.1 mg/kg of BPA 63 and ≥ 466 mg/kg/day of BPA. A dose-dependent decrease in relative (> 10%) and absolute (> 22%) liver weights was found at ≥ 466 mg/kg/day of BPA compared to controls 57,58 . In this study, the VPA group was not statistically different from sham and therefore implies a return to baseline, but that significance between the treatment groups was not seen.
The liver plays several roles in detoxification and protects the body from potentially toxic chemicals throughout xenobiotic biodegradation and metabolism. Environmental toxicants disrupt normal liver functioning, causing various diseases 18,19 . As a ubiquitous environmental toxicant, BPA damages tissues/organs in humans and animals 20,21 . BPA is shown to induce apoptosis in different mammalian cells, including, osteoclasts germ cells and osteoblasts 23,25 . HDAC treatment prevented cell loss in many in vitro and in vivo disease models [64][65][66] . In this study, BPA significantly increased histopathological scores of hepatocytes, they are representative of liver injury, and treatment with VPA after BPA exposure ameliorated liver function, attenuated liver pathology, and decreased hepatocyte apoptosis due to BPA's noxious effect.
BPA injures the liver primarily by increasing oxidative stress, increasing the inflammatory response, and inhibiting mitochondrial function 63,67 . In mammals, ROS produced as a result of aerobic metabolism exert adverse effects on host cells 68 . These ROS affects the body's capacity to effectively negate free radicals 69 . Among the body's many defense mechanisms, oxidative stress is very important, which protects mammalian cells from environmental toxicants 70 . Clinical and experimental studies have reported that the oxidative stress induced by ROS play an important role in liver injury 56,71 . Because of limited information about BPA's effects on the liver, this study investigated possible hepatotoxic effects of BPA by inducing oxidative stress. We found that BPA alters the body's oxidative status, characterized by elevated MDA and PC levels. A previous study demonstrated increased liver MDA levels in BPA exposed rats 56 . Other reports also showed increased MDA levels in the testes, brain and kidneys of BPA exposed rats 35,56 . In addition, VPA prevents the peroxidation of membrane lipids and protein carbonylation after BPA-induced liver pathology in rats and is also effective in attenuating acute lung injury caused due to ischemia-reperfusion 72 .
Cellular damage due to interaction between macromolecules such as lipids, proteins, and DNA and ROS can be inhibited by antioxidants. Therefore, overproduction of or unbalanced ROS leads to clinical disorders, which can occur as a disturbance of the redox reactions in cells as an effect of BPA, which, in turn, increases oxidative stress 73 .
GSH is an antioxidant which participates in catalysis of other antioxidants including GSH peroxidase and GSH reductase. A decrease in GSH derails antioxidant defense against free radicals 74  www.nature.com/scientificreports/ GSH levels and increased MDA levels are signs of overproduction of free radicals, which causes lipid peroxidation in the liver 75 .
In this study, we found that the antioxidant capacity in BPA-treated mice was blunted, possibly due to decreased GSH levels. Similarly, a prior study showed a decrease in GSH levels in the livers of BPA-treated rats 56 . Consistent with our findings, studies have also reported liver damage in BPA-treated rats due to decrease in GSH 63,76 . BPA is well-known to generate ROS, which cause damage to many organs 26,30 . Our results, therefore, demonstrated that BPA causes oxidative damage to the liver by derailing the balance between ROS and the antioxidants in the liver and that the HDAC2 inhibitor VPA increases cellular GSH levels in the liver decreased by BPA exposure.

Conclusion
This work highlights that BPA exposure has detrimental effects on liver tissue architecture of male mice. In addition, our findings also showed that BPA significantly promoted liver oxidative injury by disturbing oxidant/ antioxidant status, and ultimately led to liver abnormality as revealed by biochemical test and histological alterations. These findings shed light to realize possible underlying mechanism(s) on the development of a range of abnormalities induced by BPA. Importantly, the concurrent treatment by HDAC2 inhibitor VPA had protective effects on the liver tissue structure, and afforded protection against BPA toxicity. However, we were incapable of finding the precise mechanism by which VPA exerts its actions. Nevertheless, our findings imply that some impacts may be mediated by suppression of oxidative stress markers (MDA and PC) and enhancement of GSH levels upon BPA-mediated liver toxicity. Anyway, our findings suggest that VPA provides effective treatments for BPA-induced liver pathology. Further studies should provide greater knowledge for a better understanding of the protective mechanism(s) of VPA.

Materials and methods
Animals. The experiment was approved by the Research Ethics Committee, Biotechnology Research Center, Tripoli, Libya. Approval number (BEC-BTRC 8-2019). Methods were carried out in accordance with approved guidelines. All animal experiments were conducted in accordance with the ARRIVE guidelines and were performed per the National Institutes of Health Guiding Principles within the Care and Use of Animals. We used 30 adult Swiss male albino mice of 8 weeks old and weighing 27.5 ± 1.48 g. The mice were maintained under 12/12 h light/dark cycle at 26 ± 2 °C in the animal facility, Faculty of Sciences, University of Tripoli, Libya. All mice had free access to food and water.
Experimental design. We randomly divided 30 mice into five groups: group 1: SC, normal control; group 2: VC, corn oil (vehicle control); group 3: BPA group, 4 mg/kg/day of BPA (single dose; Alfa Aesar, USA) in sterile corn oil; VPA group, 4 µg/kg bw VPA: VPA group (Sigma-Aldrich, Germany) twice a week for 2 weeks; and BPA + VPA group, BPA + VPA. BPA and VPA were administrated orally to mice via gavage. Once the mice were 10 weeks old, 24 h after the last treatment, the mice were euthanized for biochemical and histological examinations (Fig. 6). BPA doses were selected on the basis of earlier studies on the toxic effects of BPA 15,77-79 .  Figure 6. Schematic of animal treatment procedure. At 8 weeks old, mice were exposed to different treatments: sham, vehicle, VPA, BPA, or BPA + VPA. BPA and VPA were administered orally via gavage at a single dose of 4 mg/kg and 4 µg/kg for 2 weeks, respectively. At 10 weeks of age, the mice were euthanized and tissues were collected for biochemical and histological examinations. VPA valproic acid, BPA bisphenol A. www.nature.com/scientificreports/ Clinical assessment. Clinical observations were made every day. Any abnormal clinical signs or behaviors due to toxicity were recorded. Animals were monitored for their survival throughout the study. Overnight death of mice was recorded following morning and mortalities not related to exposure were determined by establishing cause of death by an independent observer.
Body and liver weight measurement. The BWs were recorded before and after the end of the experimental duration, and initial and final BWs were used to calculate the BW change (%). Following the completion of treatment time livers were excised, weights were recorded and the relative BW (%) was determined.
Blood samples. Blood  and alkaline phosphatase [ALP]) were measured. The enzymatic-based method was used to measure both enzymes' activities. ALP was assayed as previously described 80 where phenylhydrazine formed is directly proportional to the enzyme quantity.
Lipid peroxidation assay. Malondialdehyde (MDA) was quantified as a thiobarbituric acid (TBA)-reactive substrate, as described previously 81,82 . Briefly, liver tissue samples were homogenized in ice-cold 10% (w/v) phosphate-buffered saline using a tissue homogenizer (IKA, RW 20.n, Germany). The suspension was spun down, 500 µL aliquots of homogenate samples were added to 2 mL of trichloroacetic acid (TCA)-TBA, HCL reagent (15% TCA, 0.37% TBA, and 0.24 N HCl), and the mixture was boiled for 15 min and allowed to cool. Mixture was centrifuged and the obtained supernatant was read at 532 nm. To obtain a calibration curve, different amounts of 1,1,3,3-tetramethoxypropane were used as standard to measure concentration of TBA-MDA adducts and the result was expressed in nmol/mL.
Protein peroxidation assay. The liver carbonyl protein content was measured spectrophotometrically using liver tissue, as described 83,84 . After the liver tissue samples were homogenized, where the final total protein content was adjusted to be less than 10 mg/mL, the samples were incubated for 1 h at room temperature in the dark with 10 mM 2-4-dinitrophenylhydrazine (DNPH) in 2.5 M HCl, in the same condition as the control samples. Protein was precipitated using 20% TCA, washed with ethanol-ethyl acetate (1:1), and redissolved using precipitated 6 M guanidine HCl. The DNP derivatization absorbance was measured at 370 nm using controls as a blank.
Glutathione measurement. GSH levels were measured using Ellman's reagent (5,5-dithiobis-(2-nitrobenzoic acid) [DTNB]), as described 85 . The liver homogenate was mixed with 25% TCA to precipitate proteins and centrifuged for 5 min at 4000 rpm. The supernatant was incubated with PBS (pH 7.4) and DTNB for 10 min. Absorbance was measured at 412 nm and the GSH levels were expressed as nmol/mg protein.
Histopathological studies and microscopy. Liver tissue was prepared for histological preparation, as previously described 86,87 . Liver tissue samples were dehydrated in a series of upgrade concentrations of ethanol solutions, cleared in xylene, and embedded in paraffin wax. Next, 5-µm-thick paraffinized sections were cut, deparaffinized, hydrated, and stained with hematoxylin and eosin (H&E). Slides were examined under microscope (Leica Microsystems, Germany). The liver tissue sections from each mouse were assessed blind by a pathologist for histopathological changes. Histopathologic investigation of liver tissue sections was performed with a focus on inflammatory changes, hepatocellular necrotic changes, biliary ductless changes, fibrosis, architecture changes, and regenerative changes. The frequency of lesions was unbiased evaluated to determine a pattern of injury and assessed semi-quantitatively according to the severity and distribution of the pathological changes.. Only diagnoses that were considered accurate based on histopathological changes and the data presented in each group were included in the histopathological description and depictions. The degree of severity of lesions was assessed as minimal (1 focus or less with 10 × objective), mild (2-4 foci with 10 × objective), moderate (5-10 foci with 10 × objective), or severe (> 10 foci with 10 × objective) according to the modified Ishak score 88 . Grading calculation of these assigned numbers to assess the severity of the necro-inflammatory features was performed, as previously described 88 . Locations without lesions were designated as normal (none). The histopathological findings were divided according to lesion possibility, staining, and histological components of the liver with reference to the detailed algorithm of Batts and Ludwig 89 . The four criteria of scoring were averaged and considered as a replicate.
Cell death scoring. Cell death was assessed using image-analysis ImageJ software (National Institutes of Health, MA, USA; http:// rsb. info. nih. gov/ ij/). Cell numbers from H&E stained liver tissue slides were calculated as a percentage of number of cells present and overall average of the cell numbers obtained from each treatment group). www.nature.com/scientificreports/ Apoptotic cells were characterized by their morphology of cell shrinkage; in addition, other cell properties were assessed, such as chromatin condensation, cellular migration rate, and apoptotic body identification 54 . Hepatocyte necrosis was assessed using the following criteria: increased cytoplasmic eosinophilia, cell swelling, karyorrhexis, and karyolysis. The apoptosis percentage was determined by counting the number of apoptotic hepatocytes throughout 40 × objective microscopic fields out of the entire histologic section. The scoring scale, 0 to 5 was set based on no necrosis, minimal, mild to moderate, moderate, moderate to severe, and severe, respectively. For quality of scoring, the final score of each liver tissue section was calculated as an average of eight scores. Statistical analysis. The Data were analyzed using GraphPad Prism software version 7.0. All data represent the mean ± SEM. Also, normality was assessed using the computerized Kolmogorov-Smirnov test. For data with normal distributions, single intragroup comparisons were made using Student's paired t test and multiple comparisons were made using one-way analysis of variance, followed by a post hoc test for multiple comparisons. Dunnett's multiple-comparison test was used to detect pairwise intergroup differences. P < 0.05 was set as statistically significant.

Data availability
Data used during the current study are available from the corresponding author.